Global Epigenetics Market, By Product (Enzymes, Instruments and Consumables, Kits, Reagents), Application (Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Others), Technology (DNA Methylation, Histone Methylation, Others), End User (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, Contract Research Organizations (CROs))-Industry Trends and Forecast to 2029.
Market Analysis and Size
Epigenetic mechanisms are being linked to an increasing number of chronic diseases and disorders, such as cardiovascular disease, autoimmune disease, and neurodegenerative disorders, as well as environmental cues and nutrition, all of which have a significant impact on epigenetic processes such as DNA methylation, histone modification, and non-coding RNA.
Data Bridge Market Research analyses that the epigenetics market was valued at USD 10.96 billion in 2021 and is further estimated to reach USD 47.75 billion by 2029, and is expected to grow at a CAGR of 20.2% during the forecast period of 2022 to 2029.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Enzymes, Instruments and Consumables, Kits, Reagents), Application (Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Others), Technology (DNA Methylation, Histone Methylation, Others), End User (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, Contract Research Organizations (CROs))
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Illumina, Inc. (US), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eisai Co., Ltd. (Japan), Novartis AG (Switzerland), Abcam plc (UK), Diagenode s.a. (US), Active Motif, Inc. (US), Zymo Research Corporation. (US), Thermo Fisher Scientific (US), Cellcentric (Germany), Syndax (US), New England Biolabs (US), Epizyme, Inc. (US), Domainex (UK), Agilent Technologies, Inc. (US), PerkinElmer Inc. (US), Bio-Rad Laboratories, Inc. US), AsisChem Inc. (US), Enzo Life Sciences, Inc. (US), EpiGentek Group Inc. (US), BioVision Inc. (US), Bio-Techne. (US), Promega Corporation (US), GeneTex, Inc. (US), Pacific Biosciences of California, Inc. (US)
|
|
Market Opportunities
|
|
Market Definition
Epigenetics is a branch of genetics concerned with the study of cellular and physiological trait variations caused by environmental or ecological factors that turn genes on and off and influence cellular ability to read genes without being affected by genotype changes. Epigenetics causes changes in an organism's phenotype rather than genotype, with the underlying DNA or RNA sequence remaining constant.
Epigenetics Market Dynamics
Drivers
- Rise in the incidence of cancer
According to the World Health Organization, over 1.8 million new cancer cases were identified worldwide in 2018. According to the World Health Organization, low- and middle-income nations have been accounted for about 70% of cancer deaths.
- Increase in the research and development
Organizations such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) are pushing financing and support for epigenetics-related research and development and commercial development.
- Growing Initiatives taken by the Government in the Field of Epigenetics
The number of academic, pharmaceutical, and biotechnology businesses collaborating on epigenetics research is growing, as is the use of epigenetics in non-oncology disorders.
Opportunities
In addition, the increase in the growth benefits in the emerging countries are further estimated to provide potential opportunities for the growth of the epigenetics market in the coming years.
Restraints/Challenges
On the other hand, the growing expenditure of instruments is further projected to impede the growth of the epigenetics market in the targeted period. However, the dearth of skilled experts might further challenge the growth of the epigenetics market in the near future.
This epigenetics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the epigenetics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Epigenetics Market
The COVID-19 had a positive impact on the epigenetics market. Although no clinically authorised medicine or vaccine exists to treat coronavirus infection, a few treatment combinations have been tested to help people survive the virus. Furthermore, targeted antiviral medicines such as remdesivir, rapamycin, and ribavirin, as well as epigenetic medications such as BRD4 inhibitors, DNMT1 inhibitors, and HDAC inhibitors, have been shown to decrease virus action. In order to develop vaccines and therapies that directly target a virus's replicating mechanisms, researchers have begun to grasp how epigenetics may limit viral multiplication. As a result, the epigenetics sector is expected to benefit from an increase in the number of epigenetic studies and increased knowledge of epigenetic medications for the treatment of coronavirus infection.
Recent Development
- In April, 2021, Eurofins Genomics India, a leading provider of genomic products and services, has announced the launch of its "SARS-CoV-2 Full-length Genome Sequencing" service, a new next-generation sequencing (NGS) service that allows for end-to-end monitoring of the coronavirus genome sequence and mutational drift.
Global Epigenetics Market Scope and Market Size
The epigenetics market is segmented on the basis of product, application, technology and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Enzymes
- Instruments and Consumables
- Kits
- Reagents
On the basis of product, the epigenetics market is segmented into enzymes, instruments and consumables, kits, reagents. Enzymes is further sub segmented into DNA-modifying enzymes, protein-modifying enzymes, RNA-modifying enzymes. Instruments and consumables is further sub segmented into next-generation sequencers, qPCR, mass spectrometers, sonicators, others. Kits is further sub segmented into bisulfite conversion kits, ChIP-sequencing kits, RNA sequencing kits, whole genomic amplification kits, 5-hmC and 5-mC analysis kits, others. Reagents is further sub segmented into antibodies, buffers, histones, magnetic beads, primers, others.
Application
- Oncology
- Metabolic Diseases
- Developmental Biology
- Immunology
- Cardiovascular Diseases
- Others
On the basis application, the epigenetics market is segmented into oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, others.
Technology
- DNA Methylation
- Histone Methylation
- Others
On the basis of technology, the epigenetics market is segmented into DNA methylation, histone methylation, others.
End User
- Academic and Research Institutes
- Pharmaceutical Companies and Biotechnology Companies
- Contract Research Organizations (CROs)
On the basis of end user, the epigenetics market is segmented into academic and research institutes, pharmaceutical companies and biotechnology companies, contract research organizations (CROs).
Epigenetics Market Regional Analysis/Insights
The epigenetics market is analysed and market size insights and trends are provided by country, product, application, technology and end user as referenced above.
The countries covered in the epigenetics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the epigenetics market due to the sustenance on the constant research activities on the epigenetics. Furthermore, the presence of innovative healthcare amenities that are provide and continuous developments in the diagnostic process will further boost the growth of the epigenetics market in the region during the forecast period.
Asia-Pacific is projected to observe significant amount of growth in the epigenetics market due to the rise in the disposable income. Moreover, the growing untapped clinical needs of the patients is further anticipated to grow of the epigenetics market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The epigenetics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for epigenetics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the epigenetics market. The data is available for historic period 2010-2020.
Competitive Landscape and Epigenetics Market Share Analysis
The epigenetics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epigenetics market.
Some of the major players operating in the epigenetics market are:
- Illumina, Inc. (US)
- Merck KGaA (Germany)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Eisai Co., Ltd. (Japan)
- Novartis AG (Switzerland)
- Abcam plc (UK)
- Diagenode s.a. (US)
- Active Motif, Inc. (US)
- Zymo Research Corporation. (US)
- Thermo Fisher Scientific (US)
- Cellcentric (Germany)
- Syndax (US)
- New England Biolabs (US)
- Epizyme, Inc. (US)
- Domainex (UK)
- Agilent Technologies, Inc. (US)
- PerkinElmer Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- AsisChem Inc. (US)
- Enzo Life Sciences, Inc. (US)
- EpiGentek Group Inc. (US)
- BioVision Inc. (US)
- Bio-Techne. (US)
- Promega Corporation (US)
- GeneTex, Inc. (US)
- Pacific Biosciences of California, Inc. (US)
SKU-